{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-pivotal-data-show-strong-and-durable-responses-in-advanced-head-and-neck-cancer-where-options-remain-limited-302786430.html", "message": "News view counter 769199 successfully enlarged"}